CURRICULUM VITAE

Jean-Pierre ALLAIN
Emeritus professor of Transfusion Medicine, Department of Haematology
University of Cambridge, Cambridge, UK

Home Address:
Date of Birth: GRO-C 1942
Place of Birth: Chateauroux, Indre, France
Nationality: French

Education
1967 University of Paris Medical School: Platelet Factor 3
Diploma in Haematology, University of Paris
1967 Diploma in Medical Microbiology, University of Paris
1968 Diploma in Medical Biochemistry, University of Paris
1971 Master's Degree in Human Biology, University of Paris
1986 PhD in Biochemistry: Immunologic and biochemical characterisation of antibodies to Factor VIII: C in man
1994 MSc in Clinical Psychology

Posts Held
1965-1967 Assistant Professor of Haematology, Hôpital St Louis, Paris
1967-1971 Assistant Professor of Haematology, Hôpital Bicêtre, University of Paris South Medical School
1971-1977 Director, French Red Cross Haemophilia Centre, La Queue Les Yvelines, France
1977–1981 Senior Research Scientist (Haemostasis), National Blood Transfusion Centre, Paris
1981-1986 Head of Department of Research & Development for plasma derivatives, National Blood Transfusion Centre, Paris
1986-1989 Medical Research Laboratory Manager (Hepatitis & AIDS Diagnostics Products), Laboratories, N. Chicago, IL, USA
1989-1991 Medical Director, AIDS & Hepatitis Division, Abbott Laboratories, N Chicago IL, USA
1991-1992 Director East Anglia Blood Transfusion Centre, Cambridge, England
1991-Sep 2009 Professor of Transfusion Medicine, Department of Haematology, University of Cambridge, Cambridge, UK
Oct 2009-present Part-time Emeritus Prof Transfusion Medicine, Dept Haematology, University of Cambridge, Cambridge, UK

Fellowship
1973-7 Department of Pathology, University of North Carolina, Chapel Hill, NC, USA
Royal College of Pathologists, 2 Carlton House Terrace, London SW1Y 5AF, England (FRCPath)
2000 Fellow Academy of Medical Sciences
1999-2000 Sabbatical leave, Dept of Medicine, Head of Blood Centre, Komfo Anokye Teaching Hospital, Kumasi, Ghana

Membership
International Society of Thrombosis and Hemostatis until 1986
International Committee in Thrombosis and Hemostasis (Consultant) until 1986
French Society of Haematology until 1986
French Society of Blood Transfusion until 1986
World Federation of Haemophilia (Medical secretary 1972-1986)
International AIDS Society

American Association of Blood Banks (AABB)
British Blood Transfusion Society
British Society for Haematology
International Association of Biological Safety (chair Blood Committee)

Other
Consultant to WHO – Blood Products until 1985
Global Consortium for Blood Safety (GCBS) 2004-2010

Scientific Journal Reviewer:
AIDS (Member of Editorial board)
AIDS Research & Human Retroviruses
Blood
Blood Transfusion (Member Editorial board)
BMC Public Health
British Journal of Haematology
Clinical & Diagnostic Virology
Clinical & Experimental Immunology
Digestive Diseases and Sciences
Emerging Infectious Diseases
Epidemiology and Infection
European Journal of Clinical Microbiology & Infectious Diseases
Haemophilia
Hepatology
Journal of American Medical Association (JAMA)
Journal of Acquired Immunodeficiency Syndrome
Journal of Clinical Microbiology
Journal of General Virology
Journal of Hepatology
Journal of Infection
Journal of Infectious Diseases (Member Editorial board)
Journal of Medical Virology
Journal of Viral Hepatitis
Journal of Virology
Journal of Virological Methods
Malaria Journal
Medical Journal of Australia
Nature Medicine
PLOS Medicine
Scandinavian journal of Infectious Diseases
Transfusion (Member Editorial board)
Transfusion Medicine (Editor in chief)
Virology
Virology Journal
The Lancet
Vox Sanguinis

Summary of Professional Activity and Experience 1964 to present

1964-1967
Junior medical resident in Paris general hospitals (Assistance publique) in surgery, internal medicine and haematology.

1967-1971
Hospital Bicetre, University of Paris V

Assistant professor of Haematology (Lecturer), adult section 1967-69
Assistant professor of Haematology, paediatric section 1969-1971
Delegated to the function of Reader in Haematology 1970-1971
Main topic of activity was laboratory haematology for Hospital patients. Some research was conducted on microscopic electronis studies of Gaucher disease. Studies of high doses of penicillin on platelet functions.

1970-1977
French Red Cross Haemophilia Centre
At the Centre, I was appointed Director with both Medical and Administrative responsibilities. The Centre consisted essentially of a boarding school for over 100 children with haemophilia A or B, mostly severe. Primary and secondary education was initially provided in the Centre by teachers specialised in education of handicapped children appointed under a special contract by the Regional Department of Education. Later, when self-treatment was introduced (1974), secondary education was provided by the local public high school.
The staff consisted of 2 MDs, 2 nurses, 4 aid nurses and a variety of external consultants (orthopaedic surgeons, dentists, neurologists, psychiatrists, and paediatricians). 2 clinical psychologists and 2 social workers provided Psychological supported. There were a total of 70 staff members.
During the two 3 year periods of my directorship, the main topics of research were:

- Haemophilic arthropathy
- Replacement therapy and evaluation of new therapeutic products
- Natural history of antibody to Factor VIII
- Characterisation of allo- and auto-antibody to Factor VIII
- Self-treatment and its psychological consequences
- Interaction between haemophilic children and their parents

In each of these topics, several peer reviewed articles were published.
The main accomplishment of the institution was to initiate and legitimise self-treatment and home treatment for haemophiliacs in France. The group demonstrated not only the medical benefit of this approach but also its major psychological impact on the children and their families. Secondly, the studies on antibody to Factor VIII were instrumental in the development of immunoassays and purification of Factor VIII leading to the cloning and expression of Factor VIII. The description of high and low responder inhibitor to Factor VIII was critical in advancing therapy of this severe complication of haemophilia A.

1977-1986
At the National Blood Transfusion Centre (CNTS) I reported to Professor J P Soulier, Director of CNTS initially and, on his retirement in 1984, to Mr G. Jacquin, Vice President of the Division of Bio Industry.
I was required to:
- Supervise and co-ordinate research and development programs of a department consisting of 4 senior scientists, 11 technicians and 5 graduate students doing thesis at master or PhD levels in the field of therapeutic blood products and protein biochemistry.
- Supervise budget, planning for new facilities, dealing with the personnel aspects of the department (25 persons).
- Be responsible for all in vivo clinical evaluation of coagulation factor preparations developed in my department and produced by CNTS. In addition, I designed and supervised clinical trials for a new fibronectin concentrate.
- Act as official liaison between CNTS and the French Haemophilia Association.
- Act as scientific committee chairman of a national programme to produce recombinant DNA Factor VIII for human therapy.
- Run a regular clinic for patients with bleeding disorders and be responsible for 30

patients with chronic haemorrhagic disorders, mostly haemophiliacs.
- Act as consultant on a national basis for difficult cases of haemophilia, particularly those with inhibitor.
- Act as a member of the National Expert Committee on Haemophilia reporting directly to the Ministry of Health. In this capacity, I designed and supervised several clinical trials evaluating Factor VIII and Factor IX preparations for the treatment of haemophiliacs at a national level. Domestic and imported products, non-heat-treated and heat-treated, were evaluated with respect to both non-A and non-B viruses and LAV/HTLC-III transmissions.
- Act as co-ordinator of the French AIDS-Haemophiliac Study Group. From 1983, this multi-centre, multidisciplinary national group evaluated the epidemiological and clinical features of LAV/HTLV-III infection in multi-transfused patients (haemophiliacs and thalassaemics). My responsibility was to design protocols for investigations, to collect results, organise co-ordination meetings, write grant proposals and scientific papers on the results. This study was supported by 3 grants from national research agencies totalling £350,000 to be shared by participants under the co-ordinator's responsibility. Four papers were published in Blood, The New England Journal of Medicine and Vox Sanguinis.
- Act as consultant to international agencies on blood and blood products (WHO, International Red Cross, World Federation of Haemophilia) and to various commercial and non-profit making organisations in the field of haemophilia and AIDS.

1986–1991
At Abbott Laboratories, N. Chicago, IL, USA
I was Manager of Medical Research from 1986 to 1989 and then Director of Medical Affairs for Hepatitis and Retroviruses from 1989 to 1991.
Medical Research consisted mostly of co-ordinating clinical investigations on current or new diagnostic products in order to determine their clinical use through designing and implementing collaborative studies with external laboratories (mostly academia). The products evaluated were:
HIV antigen
HIV p24 antibody quantification
HIV antibody quantification of antibodies to multiple structural HIV antigens
HTLV-I antibody assay and its confirmation
HBV DNA semi-quantitative assay
HCV antibody assay and its confirmation
In addition, multiple epidemiological studies were carried out. One of the main focuses of my activity was the assessment of various tests to predict progression of AIDS individually or in association. Some of these tests were found to be critical to monitor treatment of HIV infection with antiviral drugs.
I carried out a major project that consisted on the preparation, characterisation and clinical evaluation of a purified IgG fraction containing high titre of antibody to HIV for passive immune therapy. Animal studies in 3 chimpanzees and a phase I trial in 12 AIDS patients were completed successfully. An efficacy study protocol in HIV infected newborns was finalised and carried out in collaboration with the AIDS Clinical Trial Group (ACTG) of the NIH National AIDS programme.
In September 1989, I was put in charge of the Abbott Virology Reference Laboratory that provided confirmation testing for HIV-1, HIV-2, HTLV-I/II and HCV.
In April 1990, I was appointed head of the unit in charge of product clinical trials supervising 22 people including 4 PhDs. This group designed, carried out and report on field trials of new products for submission to the FDA, or national regulatory bodies, for licensure.

1991 to 2015
At Division of Transfusion Medicine, Department of Haematology, University of Cambridge
In 1991-92, I was Director of the East Anglian Blood Transfusion Centre. In that

capacity, I first restructured the Service and transformed this somnolent organisation into a dynamic, functional, cost-effective organisation, highly praised by the consultant haematologists in the region. The Centre also became recognised nationally and internationally. I was considerably helped in this task by two lecturer/consultants (Dr W Ouwehand and L Williamson) and the constant support of both the head of the Department of Haematology (Prof. RW Carrell) and the medical director of the RHA (Dr M O'Brien).
Simultaneously, we started a research unit in Transfusion Medicine (Division of Transfusion Medicine) within the Department of Haematology located in the National Blood Service facilities as an academic unit. Over a period of 3-5 years, this unit has prospered to reach a level of 30 and now 45 members, dedicated to research in transfusion Medicine. In 1995, the secretary of state for Health (Mr S Dorrell) designated this unit as well as another in Bristol Centres of excellence for research in Transfusion.
After a 13 month-interruption due to legal problems in France with regards to HIV infection in haemophiliacs, I returned to my post as Professor of Transfusion Medicine at the University of Cambridge but was relieved from my consultancy and directorship with the NHS. This happened despite the fact that two special investigation groups independently constituted by the Royal College of Pathology and the East Anglia RHA, exonerated me of any wrong doing during the 1983-85 period in France. In June, 2003, the French Supreme court dismissed the charges for HIV infection of Haemophiliacs.
I then resumed my research activity and the co-ordination of the Division of Transfusion Medicine. In 2000-2005, this unit research output was approximately 50 original peer reviewed publications. The funding of the division originates in almost equal parts from the NHS (NBS), national or charitable research funding organisations, and industry for a total budget of £2.2M/ year.

2015-present
Officially retired. Work as part-time consultant for a diagnostic start up company in Little Chesterford, Cambridgeshire.

Peer-reviewed publications

1. Allain JP, Caen J. L'analyse des fonctions plaquettaires: Mesure de l'activité coagulante des plaquettes appelée Facteur 3. Revue Francaise d'Etude Clinique et Biologique 1967; 12: 732
2. Caen J, Michel H, Hermansky F, Allain JP, Besson P. Le comportement des plaquettes sanguines de porc. Compte-rendus des séances de la Société de Biologie 1967; 161: 2455
3. Meyer D, Allain JP, Sultan Y, Caen J. Physiologie de l'hémostase I Mégacaryocytes et plaquettes. Pathologie Biologie 1968; 16: 783
4. Sultan Y, Caen J, Allain JP, Meyer D. Physiologie de l'hémostase II Fibrinolyse. Pathologie Biologie 1968; 17: 529
5. Allain JP, Meyer D, Sultan Y, Caen J. Physiologie de l'Hémostase III - Hémostase primaire. Pathologie Biologie 1970; 18: 679.
6. Allain JP. Traitement des arthropathies aigues hémophiliques. Gazette Médicale de France 1971; 19: 187.
7. Caen J, Josso F, Sultan Y, Meyer D, Allain JP. L'Hémostase - Physiologie Exploration Fonctionnelle. L'Expansion 1970.
8. Allain JP, Maillasson F, Bach Ch. Hypoconvertinémie congénitale: un nouveau cas dans une famille de déficit associé VII + X. Annales de Pédiatrie 1971; 18: 817-823.
9. Allain JP, Risse JC. Treatment of hemophilia by continuous injection of cryoprecipitate. VIIth Congress of The World Federation of Haemophilia. eds: F. Ala and K W Denson. Excerpta Medica (Amsterdam 1973) pp 254-259.
10. Allain JP, Witvoet J, Gentil C. Les étapes du traitement de l'arthropathie du genou

chez l'hémophile. Coagulation 1971; 4: 339.
11. Risse JC, Menkes C, Allain JP, Witvoet J. Synoviorthesis as treatment of chronic haemophilic arthropathy: preliminary report. Proceedings of the VIIth Congress of The World Federation of Haemophilia (Tehran 1971). Excerpta Medica (Amsterdam 1973) pp 216-219.
12. Josso F, Allain JP. Recent advances in the study of inhibitors in haemophilia. VIIth Congress of The World Federation of Haemophilia. eds: F Ala and K W Denson. Excerpta Medica (Amsterdam 1973) pp 259-265.
13. Allain JP. Etude de l'activité in vivo du Facteur VIII ou du Facteur IX après injection de différents concentrés: application pratique. Nouv Rev Fr Hémat 1972; 12: 214-249.
14. Allain JP. Traitement des arthropathies chroniques de l'hémophile. G.M de France 1972; 79: 5803.
15. Josso F, Cosson A, Gazengel C, Allain JP. Les anticoagulants circulants au cours du l'hémophilie. Revue Française de Transfusion 1972; 15: 281.
16. Meyer D, Dray L, Allain JP, Larrieu J. Le Facteur VIII (Facteur antihémophilique A). Biologie, physiologie, pathologie, génétique. Path Biol 1972; 20: 607-623.
17. Lejeune F, Allain JP, Le Coq D, Turpin F. Etude cytochimique et ultrastructurale des dyslipoidoses: a propos de 6 cas. Path Biol 1973; 21: 483.
18. Allain JP, Frommel D. Antibodies to Factor VIII. I Variations in stability of antigenantibody
complexes in hemophilia A. Blood 1973; 42: 437-444.
19. Risse JC, Allain JP, Gentil C, Alagille D. Traitement de 66 hémarthrose aigues du genou chez l'hémophile par ponction évacuatrice. Arch Franc Pediat 1973; 30: 413-422.
20. Frommel D, Gaillandre A, Allain JP. Antibodies to Factor VIII - II - Study of complexes in vitro as an index of immune reactivity. Fed Proceed 1973; 32: 1034.
21. Allain JP, Vedrenne J, Frommel D. Antibodies to Factor VIII - III - Characterisation of the immune response to iso- and hetero-antigens in hemophilia. Path Biol 1973; 21: 76-79.
22. Allain JP, Gentil C, Gutton P. Special school for hemophiliacs. Handbook of Hemophilia eds: K M Brinkhous and A Britten.. Excerpta Medica (Amsterdam 1973) pp 881-896.
23. Witvoet J, Sultan Y, Amouroux J, Allain JP. Problèmes orthopédiques et chirurgicaux actuels de l'arthropathie hémophilique. Actualités hématologiques eds: Masson 1973 pp 160-175.
24. Menkès CJ, Allain JP, Gentil C, Witvoet J, Tak Tak H, Simon E, Delbarre F. La synoviorthèse à l'acide osmique chez l'hémophile. Rev Rhum 1973; 40: 255-258.
25. Allain JP, Frommel D. Antibodies to Factor VIII. Specificity and kinetics of Iso- and hetero-antibodies in hemophilia A. Blood 1974; 44: 313-322.
26. Allain JP, Cooper HA. Aggregation of platelets fixed with paraformadehyde: a study of platelet membrane receptors. Fed Proc 1974; 33: 266.
27. Allain JP, Benamon D, Frommel D. Antigen HB dans une collectivité d'hémophiles. La présence d'anticorps previent-elle une réinfection? Ed:Masson..Actualités Transfusionnelles 1974 pp 683-687.
28. Gruyer P, Allain JP, Chassaigne M, Saint-Paul B. Intéret des pools de cryoprécipité. Ed: Masson. Actualités Transfusionnelles 1974 pp 329-330
29. Gutton P, Estrabaud M, Allain JP. Etude du remaniement des résistances psychiques de 53 adolescents hémophiles lors de l'introduction d'un progrès thérapeutique majeur (l'autoperfusion). Bull de Psychologie 1974-1975; 317: 717-740.
30. Ruggeri ZM, Mannucci PM, Allain JP, Frommel D. Preliminary trial of cyclophosphamide in the management of hemophiliacs with Factor VIII inhibitors. Ann. NY Acad Sc 1975; 240: 412-418.
31. Allain JP. A boarding school for hemophiliacs. A model for the comprehensive care of hemophilic children. Ann. N.Y. Acad. Sc. 1975; 240: 226-237.
32. Allain JP, Estrabaut M, Tran J, Gutton P. Traitement de l'hémophilie par l'auto perfusion. Etude clinique et phychologique. Nouv. Rev. Franc. Hematol. 1975; 15: 147-158.
33. Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with

paraformaldehyde: a new reagent for assay of von Willebrand Factor and platelet aggregating factor. J. Lab. Clin. Med. 1975; 85: 318-328.
34. Graham JB, Barrow ES, Roberts HR, Webster WP, Blatt PM, Buchanan P, Cederbaum AI, Allain JP, Bernett DA, Gralnick HR. "Dominant" inheritance of hemophilia A in three generations of women. Blood 1975; 46: 174-188.
35. Allain JP, Cooper HA and Wagner RH. Disappearance of canine small active Factor VIII fragment following transfusion in hemophilic dogs. Vth Congress of the International Society on Thrombosis and Haemostatis (Paris 1975); abst.
36. Brinkhous KM, Graham JB, Cooper HA, Allain JP, Wagner RH. Assay of von Willebrand Factor in von Willebrand's disease and hemophilia: use of a macroscopic platelet aggregation test. Thromb. Res. 1975; 6: 267-273.
37. Allain JP, Roberts HR. Treatment of acute bleeding episodes in hemophilic patients with Factor VIII antibodies. Handbook of Hemophilia, eds: K M Brinkhous et al. Excerpta Medica (Amsterdam 1975) pp 659-671.
38. Allain JP and Krieger G. Prothrombin-complex concentrate in treatment of classical haemophilia with Factor VIII antibody. Lancet 1975; 2: 1203.
39. Meunier L, Allain JP, Frommel D. Performances of an artificial reagent for the on-stage Factor IX assays. Thromb Diath Haemorrh 1975; 23: 547-552.
40. Meyer D, Plas A, Allain JP, Sitar J M, Larrieu M J. Problems in the detection of carriers of haemophilia A. J Clin Pathol 1975; 28: 690-695.
41. Strike L, Saint-Paul B, Chassaigne M, Allain JP. Dosage radioimmunologique du Facteur antihémophilique A. Nouv. Press Med 1975; 5: 2877-2879.
42. Allain JP and Frommel D. Antibodies to Factor VIII: patterns of immune response to Factor VIII in hemophilia A. Blood 1976; 47: 973-982.
43. Allain JP, Steinbuch M, Meunier L, Muller Y, Soulier J P. Traitement substitutif de l'hémophilie A par un nouveau concentré de Facteur VIII. Nouv Presse Med1976; 5: 1047-1050.
44. Allain JP, Frommel D. Failure of immuno suppression in a severe hemophilia B patients with a specific antibody. Throm Diath Haemorrh 1976; 36: 86-89.
45. Allain JP. Management of haemophilia in France. Thromb Diath Haemorrh 1976; 35: 553-558.
46. Frommel D, Allain JP. Genetic predisposition to develop Factor VIII antibody in classic hemophilia. Clin Immunol Immunopath 1977; 8: 34-38.
47. Allain JP. Traitement de l'hémophilie à domicile. Nouv Rev Fr Hematol 1977; 18 672-682.
48. Frommel D, Muller JY, Prou-Wartelle P, Allain JP. Possible linkage between the major histocompatibility complex and the immune response to Factor VIII in classic haemophilia. Vox Sang 1977; 33: 270-272.
49. de-la-Caffiniere JY; Allain JP; Laurian Y; Larrieu MJ. Patello-femoral syndrome in hemophiliac knee. Acta Orthop Belg. 1978; 44: 389-401
50. Delors S, Allain JP. Aspects psychologiques de l'autotraitement chez le préadolescent hémophile. Psychol Med 1978; 10: 739-748.
51. Allain JP. Dose requirement for replacement therapy in hemophilia A. Thromb Haemostas
1979; 42: 1-7.
52. Allain JP, Verroust F, Soulier JP. One or two stage assay for Factor VIII. Lancet 1979; i: 1076.
53. Lee H, Tucker D, Allain JP. Rapid isolation and purification of antibody to Factor VIII by protein A. Thromb Res 1979; 14: 925.
54. Allain JP. Effets secondaires des transfusions chez les hemophiles. Rev Fr Transfus Immunohematol 1979; 22: 77-81.
55. Allain JP - collaborator in the European study of Factor VIII antibody. Development of Factor VIII antibody in haemophilic monozygotic twins. Scand J Haematol 1979; 23: 64-68.
56. Allain JP, Verroust F, Soulier J P. In vitro and in vivo characterization of Factor VIII preparations. Vox Sang 1980; 36: 38.

57. Allain JP (co-author). The collection, fractionation, quality control and uses of blood and blood products. World Health Organisation Monograph Geneva 1981.
58. Allain JP, Gaillandre A, Lee H. Immuno-chemical characterization of antibodies to Factor VIII in hemophilic and non-hemophilic patients. J Lab Clin Med 1981; 97: 791-800.
59. Allain JP, Gaillandre A, Frommel D. Acquired hemophilia: functional study of antibody to Factor VIII. Throm. Haemost. 1981; 45: 285-289.
60. Allain JP. Genetic aspects of inhibitor formation in haemophilia. Eds: Seligsohn, Rimon and Horoszowski.. Haemophilia 1981 pp 79-85. (Castle House Publications Ltd).
61. Allain JP. Hemophilia: home therapy and its applicability in Southeast Asia. Southeast-Asian-JTrop- Med-Public-Health. 1979; 10: 295-7
62. Frommel D, Allain JP, Saint-Paul E, Muller J Y. HLA antigens and Factor VIII antibody in classic haemophilia. Thromb Haemost 1981; 46: 687-689.
63. Lerolle D, Dreyer-Duffer C, Allain JP. Anticoagulant circulant spécifique du facteur V: etude clinique, biologique et thérapeutique. Nouv Press Med 1981; 10: 1483-1487.
64. Verroust F, Adam C, Kourilsky O, Allain JP, Verroust P. Circulating immune complexes and complement levels in hemophilic children. J Clin Lab Immunol 1981; 6:127-130.
65. Canavaggio M, Allain JP, Lee H. Measurement of human fibronectin by enzyme-immunoassay using monoclonal antibodies. Eds: Avreameas et al.. Immunoenzymatic Techniques [Elsevier Biomedical Press] Amsterdam 1981 pp 325-328.
66. Laurian Y, Girma JP, Allain JP, Verroust F, Larrieu MJ. Absences of anamnestic response after transfusion of washed red blood cells in haemophilia A patients with antibody to Factor VIII. Scand J Haematol 1982; 28: 233-237.
67. Verroust F, Allain JP. Immune response induced by porcine Factor VIII in severe hemophiliacs with antibody to F. VIII. Thromb Haemostasis 1982; 48:238. 66.
68. Allain JP, Croissant MP, Lerolle D, Houbouyan L, Zuzel M, Frommel D. In vivo interactions of autoantibodies to Factor VIII with the Factor VIII complex. Thromb. Haemostasis 1982; 48: 142-145
69. Allain JP, Lejars A, Pham CT, Gaillandre A, Lee H. Purification de la fibronectine humaine par précipitation et immunoadsorption. Rev. Fr. Transf. et Immunohématol. 1983; 26: 123-134.
70. Croissant M, Zuzel M, Allain JP. Heterogeneity of autoantibodies to Factor VIII: differences in specificity for apparently distinct antigenic determinants of Factor VIII coagulant protein. Blood 1983; 62: 133-140.
71. Frommel D, Allain JP, Courouce AM, Derose S, Trepo D, Crivelli O, Rizetto M. Long-lasting abatement of HBsAg synthesis induced by acute delta infection. Lancet 1983; i: 656-657.
72. Lorenzini JP, Allain JP, Chalopin J M, Rifle G, Devilliers E, Carli P M, Corter P, Bonhomme J. Anticorps facteur VIII au cours d'une maladie de Rosai-Dorfman. Nouv. Rev Fr Hématol 1983; 25: 23-26.
73. Habibi-B, Allain-JP, Courouce-AM. Transfusion sanguine et syndrome d'immunodepression acquise (SIDA). Rev Fr Transfus Immunohematol 1983; 26: 447-65.
74. Allain JP, Croissant MP, Lerolle D, Houbouyan L, Zuzel M, Frommel D. In vivo interactions of autoantibodies to factor VIII with the factor VIII complex. Thromb-Haemost 1982; 48: 142-5
75. Allain JP. Preparation and clinical use of new plasma protein concentrates: antithrombin III and fibronectin. Vox Sang 1984; 46: 23-25.
76. Allain JP. Principles of in vivo recovery and survival studies. Scand. J. Haematol. 1984; 33: 1611-1613.
77. Allain JP. Production of antihemophilic factor in France. Scand. J. Haematol. 1984; 33: 499-503.
78. Allain JP. The nature of antibody response. Scand. J. Haematol. 1984; 33: 177-179.
Garretta M, Allain JP, Habibi B, Muller JY. Clinical trials in blood transfusion. Vox Sang 1984; 46: 77-80.
79. Allain JP, Verroust F. The response of Factor VIII infusion in inhibitor patients with Factor VIII inhibitors. Prog Clin Biol Res 1984; 150: 99-108.

80. Allain JP. Transfusion support for haemophiliacs. Clinics in Haematology 1984; 13: 100-117.
81. Allain JP, Duermeyer W, Hellings JA, Gazengel C, Laurian Y, Verroust F. Non-A, non-B hepatitis in hemophilic patients with inhibitor treated with activated prothrombin complex concentrates. Vox Sang 1984; 47: 47-53.
82. Allain JP, Bernard JP, Frommel D, Laurian Y, Proust JP. Prevention of early familial maladjustment by parent-staff group meetings. Scand J Haematol 1984; 33: 83-86.
83. Allain JP. Principles of in vivo recovery and survival studies in Factor VIII concentrates and their clotting activity. Eds: I M Nilsson, T W Barrowcliffe, K Schimpf. Scand J Haematol 1984; 33: 123-130.
84. Allain JP. Non-Factor VIII related constituants in Factor VIII concentrates and their clotting activity. Eds: I M Nilsson, T W Barrowcliffe, K Schimpf. Scand. J. Haematol. 1984; 33: 173-180.
85. Pierrot M, Habibi B, Allain JP, Fabre F, Casteran R. Fibronectine humaine dans le traitement des états septiques. Presse Med. 1985; 14: 79-82.
86. Verroust F, Moussard C, Allain JP. Hémorragies articulaires et musculaires des hémophiles A avec anticorps anti-Facteur VIII. Traitement par des lots sélectionnés de PPSB (concentré de Facteur IX). Presse Med 1985; 14: 1073-1076.
87. Allain JP, Masson P L, Dolkaert R E. The case for heat-treated products. Lancet 1985; 1: 814-815.
88. Allain JP, Laurian Y, Verroust F, Lambert T, Larrieu M J. Open trials with PCC and APCC: cost benefit assessment. Proc. 4th Intl. Symp Hemophilia Treatment. Eds: Maruzen & Co. (Tokyo 1985) pp 197-203.
89. Allain JP. Factor VIII concentrates. Progress in Transfusion Medicine. Ed: J D Cash. 1985 pp 108-122.
90. Soulier JP, Prou O, Allain JP. Effondrement de la fibronectine plasmatique au cours de forms graves de paludisme a Plasmodium falciparum. Presse Med 1985; 14: 1199-200.
Allain JP. Histoire naturelle des anticorps anti facteur VIII chez les hemophiles A. Rev-Fr-Transfus-Immunohematol. 1985; 28: 581-9.
91. Allain JP. Syndrome de deficit immunitaire acquis. Recommandations d'un groupe de medecins francais et specialistes de l'hemophilie. Pont a Mousson le 1er Juin 1985. Nouv-Rev-Fr-Hematol. 1985; 27: 347-9.
92. Allain JP - collaborator in the AIDS Hemophilia French Study Group. Immunologic and virologic status of multitransfused patients: role of type and origin of blood products. Blood 1985; 66: 896-901.
93. Allain JP - collaborator in the AIDS Hemophilia French Study Group. Natural history of primary infection with LAV in multitransfused patients. Blood 1986; 68: 89-94.
94. Allain JP. Prevalence of HTLV-III/LAV antibodies in patients with hemophilia and in their sexual partners in France. N Engl J Med 1986; 315: 517.
Allain JP, Laurian Y, Paul DA, Senn D. Serological markers in early stages of human immunodeficiency virus infection in hemophiliacs. Lancet 1986; 2: 1233-1236.
95. Chaisson R, Allain JP, Leuther M, Volberding P. Significant changes in HIV antigen level in the serum of patients treated with azidothymidine. N Engl J Med 1986; 315: 1610.
96. Fine JM, Allain JP, Rochu D, Marneux J. Occurrence of normal circulating pro-albumin in a hemophilia A patient after acute hepatitis related to the delta virus. Clin Chem 1986; 32: 1991-1993.
97. Allain JP. LAV infection by blood and blood derivatives. Acquired Immunodeficiency Syndrome Eds: J C Gluckman, R E Vilmer. Elsevier Biomedical Press 1986 pp 167-171.
98. Cao Y, Valentine F, Hojvat S, Allain JP, Rubenstein P, Mirabile M, Czeluzniak C, Leuther M, Baker L, Friedman-Kien AE. Detection of HIV antigen and specific antibodies to HIV core and envelope proteins in sera of patients with HIV infection. Blood 1987; 70: 575-578.
99. Allain JP, Laurian Y, Paul DA, Verroust F, Leuther M, Gazengel C, Senn D, Larrieu MJ, Bosser C. Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. N Engl J Med 1987; 317: 1114-1121.

100. Allain JP, Frommel D, Bosser C, Gazengel C, Larrieu M J, Sultan Y. The role of HIV infectivity and composition of Factor VIII concentrates on the immunity of haemophiliacs positive for HIV antibodies. Vox Sang 1987; 53: 37-43.
101 Blomback M, Kjellman H, Allain JP, Hedner U, Schimpf K, Wiechel B. On the unreliability of one-stage factor VIII:C clotting assays after infusion of factor VIII concentrates. Scand J Clin Lab Invest 1987; 47: 561-6.
102. Baillou A, Barin F, Allain JP, Petat E, Kocheleff P, Kadende P, Goudeau A. Human immunodeficiency virus antigenemia in patients with AIDS and AIDS-related disorders: a comparison between European and Central African populations. J Inf Dis 1987; 156: 830-833.
103. Ranki A, Valle SL, Krohn J, Antonen J, Allain JP, Leuther M, Franchini G, Krohn K. Long latency precedes overt seroconversion in sexually transmitted human immunodeficiency infection. Lancet 1987; 2: 589-593.
108. Regnault V, Rivat C, Vallet JP, Francois-Gerard C, Brochier G, Allain JP. A potential new procedure for removing anti-Factor VIII antibodies from hemophilia plasma. Thromb. Res. 1987; 45: 51-57.
109. Moss AR, Bacchetti P, Osmond D, Krumpf W, Chaisson R E, Stites D, Wilber J, Allain JP, Carlson J. Seropositivity for HIV and the development of AIDS or AIDS-related condition: three year follow-up the San Francisco General Hospital Cohort. Brit Med J 1988; 296: 745-749.
110. Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain JP, Wills RJ, McNeely NC, Mitsuya H, Pluda JM, Lawley TJ, Leuther M, Safai B, Collins JM, Meyers CE, Broder S. Phase I studies of 2' - 3' -dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988; 1: 76-81.
111. Surbone A, Yarchoan R, McAtte N, Bluma R, Maha M, Allain JP, Thomas RV, Mitsuya H, Nusinoff-Lehrman S, Leuther M, Pluda JM, Jacobsen FK, Kessler HA, Myers CE, Broder S. Treatment of ten acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3' -Azidop - 2', 3' dodeoxythymidine (Azidothymidine or Zidovudine) and acyclovir. Ann. Intern. Med. 1988; 108: 534-540.
112. Allain JP, Hojvat S. Development of HIV serology. Eds: L M de la Maza and E M Peterson. Medical Virology VII (Elsevier Science Publ.) 1988, pp 315-331.
113. Allain JP , Daniels R. Compulsory premarital screening HIV. JAMA 1988; 259: 1011.
114. Stramer SL, Heller JS, Coombs RW, Ho D, Allain JP. Transmission of HIV by blood transfusion. N Eng Med J 1988; 319: 513.
115. Kadhom N, Wolfrom C, Gautier M, Allain JP, Frommel D. Factor VIII procoagulant antigen in human tissues. Thromb Haemost 1988; 59: 289-94.
116. Allain JP. Advances in plasma screening of HIV markers. Complications of hemophilia therapy: new strategies for risk reduction. J Robinson Publ. Audio Visual Medical Marketing Inc 1988 pp 20-23.
117. Allain JP. Predicting AIDS in HIV-positive hemophiliacs. Human sexuality 1998 pp 12.
118. Allain JP, Gallo RC, Montagnier L. Human retroviruses and diseases they cause. Excerpta Medica 1988.
119. Parks WP, Parks ES, Fischl MA, Leuther MD, Allain JP, Nusinoff-Lehrman S, Barry D W, Makuch RW. HIV-1 inhibition by Azidothymidine in a concurrently randomized placebo controlled trial. JAIDS 1988; 1: 125-130.
120. Chaisson RE, Leuther MD, Allain JP, Nusinoff-Lehrman S, Boone GS, Feigal D, Volberding P. Effect of Zidovudine on serum human immunodeficiency virus core antigen levels. Results form a placebo-controlled trial. Arch Int Med 1988; 148: 2151-2153.
121. Perez G, Ortiz-Interian C, Lee H, de Medina M, Cerney M, Allain JP, Schiff E, Parks E, Bourgoignie JJ. Human immunodeficiency virus and human T-cell leukaemia virus type-I in patients undergoing maintenance hemodialysis in Miami. Am. J. Kidney Dis. 1989; 14: 39-43.
122. Lee H, Anderson E, Allain JP, Gonzaga A. HTLV-I infection in Brazil. Blood 1989; 73: 1742-1746.
123. Stramer SL, Heller JS, Coombs RW, Parry JV, Ho DD, Allain JP. Markers of HIV

infection prior to IgG antibody seropositivity. JAMA 1989; 262: 64-69.
124. Yarchoan R, Mitsuya H, Thomas R V, Pluda JM, Hartman NR, Perno CF, Marczyk KS, Allain JP, Johns G, Broder S. In vivo activity against HIV and favorable toxicity profile of 2' -3' dideoxyinosine. Science 1989; 245: 412-415.
125. Coombs R, Collier A C, Allain JP, Nikora B, Leuther M, Gjerset GF, Corey L. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989; 321: 1626-1631.
126. Allain JP. Treatment of HIV infection with antiviral drugs. Clin Lab Science 1989; 2: 304-306.
127. Allain JP. Hémophilie et déficit immunitaire acquis. La Revue du Praticien 1989; 39: 2674-2677.
128. Perez G, Ortiz-Interian C, Bourgoignie JJ, Lee H, de Medina M, Allain JP, Schiff E, Parks E, Roth D, Migram M, Esquerazi V, Miller J. HIV-1 and HTLV-I infection in renal transplant recipients. J. AIDS 1990; 8: 35-40.
129. Shih JWK, Lee HH, Falchek M, Canavaggio M, Jett BW, Allain JP, Alter HJ. Transfusiontransmitted HTLV-I/II infection in patients undergoing open-heart surgery. Blood 1990; 75: 546-549.
130. Yarchoan R, Mitsuya H, Pluda JM, Marczyk KS, Thomas RV, Hartman NR, Browers P, Perno CF, Allain JP, Johns DG, Broder S. The National Cancer Institute Phase I Study of ddi in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev Inf Dis 1990; 12: 5522-5533.
131. Lee HH, Weiss SH, Brown LS, Mildvan D, Shorty V, Saravolatz L, Chu A, Ginsburg H M, Markowitz N, des Jarlais DC, Blattner WA, Allain JP. Prevalence of HIV-1 and HTLV-I/II in 5 groups of intravenous drug abuser from the Eastern and Central regions of the United States. J Inf Dis 1990; 162: 347-352.
132. Bahraoui E, Benjouad A, Sabatier JM, Allain JP, Laurian Y, Montagnier L, Gluckman J C. Relevance of anti-nef antibody detection as an early serological marker of HIV infection. Blood 1990; 76: 257-264.
133. Canavaggio M, Leckie G, Allain JP, Steaffens J, Laurian Y, Brettler D, Lee HH. The prevalence of antibody to HTLV-I/II in US plasma donors in US and French hemophiliacs. Transfusion 1990; 30: 780-782.
134. Hewlett IK, Laurian Y, Epstein J, Hawthorne A, Ruta M, Allain JP. Assessment by gene amplification and serological markers of transmission of HIV-1 from hemophiliacs to their sex partners and secondarily to their children. J. AIDS 1990; 3: 714-720.
135. Perez G, Ortiz-Interian C, Bourgoignie JJ, Lee H, de Medina M, Allain JP, Schiff E, Parks E, Roth D, Milgrom M, Esquenazi V, Miller J. HIV-1 and HTLV-I infection in renal transplant recipients. J Acq Imm Def Syndr 1990; 3: 35-40.
136. Busch MP, Taylor PE, Lenes BA, Kleinman SH, Stuart M, Stevens CE, Tomasulo PA, Allain JP, Hollingsworth CG, Mosley JW and the Transfusion Safety Study Group. Screening of selected male blood donors for p24 antigen of human immunodeficiency virus type-1. N. Engl. J. Med. 1990; 323: 1308-1312.
137. Yarchoan R, Mitsuya H, Thomas RV, Pluda JM, Hartman NR, Perno CF, Marczyk KS, Allain JP, Johns DG, Broder S. Administration of 2'3'-dideoxyinosine (DDL) to patients with severa HIV infection. AIDS Res Human Retroviruses 1990; 6: 124-125
138. Cummins LM, Weinhold KJ, Matthews TJ, Langlois AJ, Perno CF, Condie RM, Allain JP. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood 1991; 77: 111-116.
139. Brown LS Jr, Chu A, Lee H, Allain JP. Hematological indices in a cohort of HTLV-I/II and HIV-1 infected intravenous drug users in New York City. J Natl Med Assoc 1991; 83: 677-9
140. Allain JP, Laurian Y, Einstein MH, Braun BP, Delaney SR, Stephens JE, Daloga CK, Dahlen SJ, Knigge KM. Monitoring of specific antibodies to human immunodeficiency virus structural proteins: clinical significance. Blood 1991; 77: 118-122.
141. Brown LS, Chu A, Allain JP, Lee H, Cerucy M, Nemoto T. Seroepidemiology and clinical aspects of human T-cell lymphotropic virus type I/II infection in a cohort of intravenous drug users in New York City. New York State Journal of Medicine 1991; 91: 93-

97.
142. Jackson BJ, Guay L, Goldfarb J, Olness K, Mdugwa C, Mmiso F, Kataaha P, Allain JP. Hepatitis C virus antibody in HIV-1 infected Ugandan mothers. Lancet 1991; 337: 551.
Sheppard MW, Asher MS, Allain JP. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. JAIDS 1991; 4: 704-11.
143. McRae B, Lange JAM, Ascher MS, de Wolf F, Sheppard MW, Goudsmit J, Allain JP. Immune response to HIV p24 core protein during the early phases of human immunodeficiency virus infection. AIDS Res Human Retroviruses 1991; 7: 637-643.
144. Allain JP, Dailey SH, Laurian Y, Vallari DS, Rafowicz A, Desai SM, Devare SG. Evidence for persistent hepatitis C virus (HCV) infection in hemophiliacs. J Clin Invest 1991; 8: 1672-1679.
145. Allain JP, Coghlan PJ, Kenrick KG, Whitson K, Keller A, Cooper GJ, Vallari DS, Delaney SR, Kuhns MC. Prediction of hepatitis C virus infectivity in seropositive Australian blood donors by supplemental immunoassays and detection of viral RNA. Blood 1991; 78: 2462-2468.
146. Henrard DR, Mehaffey WF, Allain JP. A sensitive viral capture assay for detection of plasma viremia in HIV-infected individuals. AIDS Res Hum Retrov 1992; 8: 47 -52.
147. Smith D, Delaney S, Allain JP, Vallari D, Lee H. A comparison of two supplemental procedures for confirmation of antibody to hepatitis C virus c100-3 antigen in Louisiana blood donors. Transfusion 1992; 32: 415-419.
148. Allain JP, Rankin A, Kuhns MC, McNamara A. Clinical importance of HCV confirmatory testing in blood donors. Lancet 1992; 339: 1171 - 1172 (letter).
149. Lelie PN, Cuypers TH, Reesink HW, van der Poel C, Winkel I, Bakker E, van Exel-Oehlers, Vallari D, Allain JP, Mimms L. Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second generation HCV assays. J Med Virol 1992; 37: 203-209.
150. Laurian Y, Blanc A, Delaney SR, Allain JP. All exposed hemophiliacs have markers of HCV. Vox Sang 1992; 62: 55-56 (letter).
151. Allain JP, Hodges W, Einstein M, Geisler J, Neilly C, Delaney S, Hodges B, Lee H. Antibody to HIV-1, HTLV-I and HCV in three populations of rural Haitians. J Acq Im Defic Syndr 1992; 5: 1230-1236.
152. Busch MP, Henrard DR, Hewlett IK, Mehaffey WF, Epstein JS, Allain JP, Lee TH. Evaluation of sensitivity, specificity and reproducibility of HIV-1 DNA detection in serum or plasma using the polymerase chain reaction. J Acq Imm Defic Syndr 1992; 5: 872-877.
153. Goffin E, Oliveira DBG, Alexander GJM, Wreghitt T, Lockwood CM, Keogan M, Allain JP. Association of type III cryoglobulinaemia and hepatitis C virus-related cirrhosis. J Intern Med 1992; 232: 284-285 (letter)
154. Henrard DR, Laurian Y, Mehaffey WF, Allain JP. Lack of detection of human immunodeficiency virus type 1 DNA by polymerase chain reaction in the plasma and lymphocytes of seronegative exposed hemophiliacs. Transfusion. 1993; 33: 405-8.
155. Kleinman S, Swanson P, Allain JP, Lee H. Transfusion transmission of human T-lymphotropic virus types I and II: serologic and polymerase chain reaction results in recipients identified through look-back investigations. Transfusion 1993; 33: 14-18.
156. Allain JP. Early infection and serological markers associated with HIV infection. J Clin Apheresis 1993; 8:7-12.
157. Quaranta JF, Delaney SR, Alleman S, Cassuto JP, Dellamonica P, Allain JP. Prevalence of antibody to hepatitis C virus (HCV) and HIV-1 infected patients (Nice Seroco Cohort). J Med Virol.1994; 42: 29-32.
158. Walton JD, Caffrey EA, Allain JP. A comparative study of plateletpheresis using Baxter authopheresis C and Haemonetics PCS plus. Transfusion Medicine 1994; 4: 57-61.
159. Wreghitt TG, Gray JJ, Allain JP, Poulain J, Garson JA, Deville R, Maple C, Parameshwar J, Calne RY, Wallwork J and Alexander GJM. Transmission of hepatitis C virus by organ transplantation in the United Kingdom. J Hepatol 1994; 20: 768-772.
160. Allain JP. Haemophilia and AIDS: Historical annotation. Haemophilia 1995; 1: 145-152.
Allain JP. Molecular diagnostics for infectious diseases: new approaches and applications.

Trends in Biotechnology 1995; 13: 143-145.
161. Williamson L M, Allain JP. Virally inactivated fresh frozen plasma. Vox Sang. 1995; 69: 159-165.
162. Allain JP, Reeves I, Kitchen AD, Wenham D, Williamson LM. Feasibility and usefulness of an efficient anti-HBc screening programme in blood donors. Transfusion Medicine 1995; 5: 259-265.
163. Allain JP. Can the recombinant immunoblot assay generate an erroneous diagnosis of hepatitis C virus infection? Transfusion 1996; 36: 476-477 (letter).
164. Allain JP. Future trends for provision of safer blood components/blood products. Transfusion Sci. 1996; 3: 335.
165. Chan SW, Bye JM, Jackson P, Allain JP. Human recombinant antibodies specific for hepatitis C virus core and envelope E2 peptides from an immune phage display library. J. Gen Virol 1996; 77: 2531-2539.
166. Allain JP, Kitchen A, Aloysius S, Reeves I, Petrik J, Barbara JAJ, Williamson LM. Safety and efficacy of hepatitis C virus antibody screening of blood donors with two sequential screening assays. Transfusion 1996; 36: 401-405.
167. Lawal Z, Petrik J, Wong VS, Alexander GJM, Allain JP. Hepatitis C virus genome variability in untreated and immunosuppressed patients. Virology 1997; 228: 107-111.
168. Petrik J, Pearson GJM, Allain JP. High throughput PCR detection of HCV based on semiautomated multi-sample RNA capture. J Virol Methods 1997; 64: 147-159.
169. Allain JP and Williamson LM. How can we best achieve optimal transfusion practice? Med. J. Australia 1997; 167: 462-463.
170. Allain JP. Human plasma derivatives for developing countries. Transfusion Today 1997; 33: 10-11.
171. Jackson P, Petrik J, Alexander GJM, Pearson G, Allain JP. Reactivity of synthetic peptides representing selected sections of hepatitis C virus core and envelope proteins with a panel of hepatitis C virus-seropositive human plasma. J Med Virol 1997; 51: 67-69.
172. Lee HH, Shih J, O'Donnell D, Swanson P, Mann T, Allain JP. Differential serological diagnosis of HTLV-1 and HTLV-II infection by external membrane protein peptide-based enzyme immunoassays. Clin Diag Virol 1997; 8: 9-16.
173. Hewitt PE, Barbara JA, Soldan K, Allain JP, Dow BC. Unexplained hepatitis C virus antibody detection with various confirmatory assays. Transfusion 1997; 37: 987-988.
174. Rogers PM, Saldanha J, Allain JP. Report of EPFA/NIBSC Workshop 'Nucleic Acid Amplification Tests (NAT) for the detection of blood-borne viruses' held on 31 October 1996 in Amsterdam, The Netherlands. Vox Sang. 1997; 72: 199-206 (Review).
175. Keeling DM, Luddington R, Allain JP, Lawrie AS; Williamson LM. Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method. Br J Haematol. 1997; 96: 194-7.
176. Allain JP, Hewitt PE, Barbara JAJ, Dow BC, Follett EAC, Davidson F. Reproducibility of hepatitis C virus antibody detection with various confirmatory assays. Transfusion 1997; 37: 969-990.
Allain JP. Screening blood donors for markers of new viruses. Lancet 1997; 349: 584-585.
177. Allain JP. Historical annotation: Cryoprecipitate and the plastic blood-bag system. Haemophilia 1998; 4: 138-141.
178. Allain JP. Emerging virus in blood transfusion. Vox Sang 1998; 74: 125-129 (State of the Art Paper).
179. Allain JP, Palmer CR, Pearson G. Epidemiological study of latent and recent infection by toxoplasma gondii in pregnant women from a regional population in the U.K. J Infection 1998; 36: 189-196.
180. Petrik J, Guella L, Wight DGD, Pearson GM, Hinton J, Parker H, Allain JP, Alexander GJM. Hepatic histology in hepatitis C virus carriers coinfected with hepatitis G virus. GUT 1998; 42: 103-106.
181. Kanmogne G, Sangare A, d'Almeida O, Adu-Sarkodie Y, Davies F, Lee H, Allain JP. Human Tcell leukaemia/lymphoma virus type I infection in West African patients with clinical AIDS. AIDS 1998; 12: 2241.

182. Allain JP. Screening blood for viral genomes: which way to go? Transfusion Medicine 1998; 8: 5-7 (editorial).
183. Allain JP. The status of hepatitis C virus screening. Transfusion Medicine Reviews 1998; 12: 46-55.
184. Prati D, Zanella A, Farma E, de Mattei C, Bosoni P, Zappa M, Picone A, Mozzi F, Rebulla P, Cappellini MD, Allain JP, Sirchia G. A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous ß-Thalassaemia. Blood 1998; 92: 3460-3464.
185. Freeman JW, Williamson LM, Llewellyn C, Fisher N, Allain JP, Bellamy M, Baglin TP, Kline J, Ala FA, Smith N, Neuberger J, Wreghitt T. A randomized trial of solvent/detergent and standard fresh frozen plasma in the treatment of the coagulopathy seen during Orthotopic Liver Transplantation. Vox Sanguinis 1998; 74: 225-229.
186. Lee HH, Allain JP. Genomic screening for blood-borne viruses in transfusion settings. Vox Sanguinis 1998; 74: 119-123.
187. Davies FJ, d'Almeida O, Timmers E, d'Almeida J, Fasken M, Bassabi K, Lee H and Allain JP. Molecular Genotyping of HIV-1 in 61 patients with AIDS from Lomé, Togo. J Med Virol 1999; 57: 25-30.
188. Prati D, Lin YH, De Mattei C, Liu JK, Farma E, Ramaswamy L, Zanella A, Lee H, Rebulla P, Allain JP, Sirchia G, Chen B. A prospective study on TT virus infection in transfusion-dependent patients with beta-thalassemia. Blood 1999; 93: 1502-1505.
189. Zhai W, Davies J, Shang DZ, Chan SW, Allain JP. Human recombinant single-chain antibody fragments, specific for the hypervariable region 1 of hepatitis C virus, from immune phage-display libraries. J Vir Hepatitis 1999; 6: 115-12.
190. Petrik J, Hewitt P, Barbara J, Allain JP. Large-scale HCV RNA Screening in First-Time Blood Donors: The First Step Towards Genomic Screening of Blood Donations. Vox Sanguinis 1999; 76: 159-162.
191. Murthy KK, Henrard DR, Eichberg JW, Cobb KE, Busch MP, Allain JP, Alter HJ. Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion 1999; 39: 688-693.
192. Majid A, Jackson P, Lawal Z, Pearson GM, Parker H, Alexander GJ, Allain JP, Petrik J Ontogeny of hepatitis C virus (HCV) hypervariable region 1 (HVR1) heterogeneity and HVR1 antibody responses over a 3-year period in a patient infected with HCV type 2b. J Gen Virol 1999 ; 80: 317-25.
193. Shang D, Zhai W, Allain JP. Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the Hepatitis C virus in rabbits. Virology 1999; 258: 396-405.
194. Muller-Breitkreutz K, Baylis SA, Allain JP. Nucleic Acid amplification tests for the detection of blood-borne viruses. 5th EPFA/NIBSC Workshop, Amsterdam 1998. Vox Sanguinis 1999; 76: 194-200.
195. Allain JP, Zhai W, Shang D, Timmers E, Alexander GJ. Hypervariable region diversity of hepatitis C virus and humoral response: comparison between patients with or without cirrhosis. J Med Virol 1999; 59: 25-31.
196. Williamson LM, Llewelyn CA, Fisher NC, Allain JP, Bellamy MC, Baglin TP, Freeman-J; Klinck JR, Ala FA, Smith N, Neuberger J, Wreghitt TG. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999; 39: 1227-34
197. Muller-Breitkreutz K, Allain JP. Sixth EPFA/NIBSC workshop on NAT in Rome 1999: outcome of discussions. Biologicals. 1999; 27: 349-52
198. Allain JP, Hewitt PE, Tedder RS, Williamson LM. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haematol 1999; 107:186-95
199. Hunter JM, Allain JP, Akehurst RL. Autologous transfusion – 3 years on: What is new? What has happened? (Consensus Statement). Transfusion Medicine 1999; 9: 285-286.
200. Shang D, Lin Y H, Rigopoulou I, Chen B, Alexander GJM, Allain JP. Detection of TT virus DNA in patients with liver disease and recipients of liver transplant. J Med Virol 2000;

61: 455-461.
201. Allain JP, Dong Y, Vandamme AM, Moulton V, Salemi M. Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters. J Virol 2000; 74: 2541-9.
202. Allain JP. Cost and Public Perception. Chapter in Advances in Transfusion Safety. Brown F, Vyas G (eds). Development in Biologicals 2000; 102.
203. Allain JP. Will genome detection replace serology in blood screening for microbial agents? Baillieres Best Pract Res Clin Haematol 2000; 13:615-29.
204. Allain JP. Emerging viral infections relevant to transfusion medicine. Blood Rev 2000; 14:173-181.
205. Soldan K, Gay NJ, Allain JP, Llewelyn C, Jones C, Reeves I, Ramsay M: The prevalence of hepatitis B infection in adults with no recognised increased risk of infection. J Infect 2000; 41:198-9.
206. Allain JP. Emerging Viruses in blood transfusion. Vox Sanguinis State-of-the-Art Paper 2000; 78: 243-248.
207. Allain JP. Genomic screening for blood-borne viruses in transfusion settings. Clin Lab Haematol. 2000; 22: 1-10.
208. Candotti D, Adu-Sarkodie Y, Davies F, Baldrich-Rubio E, Lee H, Allain JP. AIDS in an HIV antibody seronegative Ghanaian woman. J Med Virol 2000; 62: 1-8.
209. Baldrich-Rubio E, Anagonou S, Stirrups K, Lafia E, Candotti D, Lee H, Allain JP. A complex HIV-1 A/G/J recombinant virus isolated in a seronegative patient with AIDS from Benin. J Gen Virol 2001; 82: 1095-1106.
210. Adu-Sarkodie Y, Sarkodie F, Acheampong JW, Allain JP. HIV p-24 antigenaemia in blood donors. Ghana Med J 2001; 35: 78-84
211. Candotti D, Sarkodie F, Allain JP. Residual risk of HIV and HCV transmission by transfusion in Ghana. Brit J Haemat 2001; 113: 37-39.
212. Candotti D, Mundy C, Kadewele G, Nkhoma W, Bates I, Allain JP. Serologic and molecular screening for viruses in blood donors from Ntcheu, Malawi: high prevalence of HIV-1 subtype C and of markers of hepatitis B and C viruses. J Med Virol 2001; 65: 1-5
213. Sarkodie F, Adarkwa M, Adu-Sarkodie Y, Candotti D, Acheampong JW, Allain JP. Screening for viral markers in volunteer and replacement blood donors in West Africa. Vox Sanguinis 2001; 80: 142-147.
214. Hamaia S, Li C, Allain JP. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Binding of free Hepatitis C virus to CD81 expressing and nonexpressing human cell lines and platelets. Blood 2001, 98: 1-8.
215. Li C, Candotti D, Allain JP. Production and characterisation of monoclonal antibodies specific to a conserved epitope within hypervariable region 1 of hepatitis C virus. J Virol 2001; 75: 12412-20.
216. Allain JP, Seghatchian J. Current strategies on pathogen removal/inactivation: an overview. Transfus Apheresis Sci. 2001; 25: 195-7.
217. Seghatchian J, Allain JP. Current strategies for the provision of safer plasma and its derivatives: an update. Transfus Apheresis Sci. 2001; 25: 185-7..
218. Pennington J, Taylor GP, Sutherland J, Davis RE, Seghatchian J, Allain JP, Williamson LM. Persistence of HTLV-I in blood components after leucocyte depletion. Blood 2002; 100: 677-681.
219. Lelie NP, van Drimmelen HAJ, Cuypers HTM, Best SJ, Stramer SL, Hyland C, Allain JP, Montcharmont P, Defer C, Nubling M, Glauser A, ds Silva Cardoso M, Viret JF, Lankinene MH, Grillner L, Wirthmuller U, Coste J, Shottstedt V, Masacar B, Dax EM. Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion 2002; 42: 527-536.
220. Opare-Sem O, Owusu-Ofori S, Allain JP. A novel approach to blood safety: pre-donation screening of blood donors for viral markers. Africa Sanguine 2002; 5: 12-6.
221. Allain JP, Williamson LM. Infectious dose of HTLV-I in transfusion recipients. Blood 2003; 101: 370-1.
222. Candotti D, Richetin A, Cant B, Temple J, Sims C, Reeves I, Barbara JAJ, Allain JP.

Evaluation of a transcription-mediated amplification-based HCV and HIV-1 RNA duplex assay for screening individual blood donations: a comparison with a minipool testing system. Transfusion 2003; 43: 215-25.
223. Allain JP, Candotti D, Soldan K, Sarkodie F, Phelps B, Giachetti C, Shyamala V, Yeboah F, Anokwa M, Owusu-Ofori S, Opare-Sem O. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 2003; 101: 2419-25.
224. Allain JP. Transfusion risks of yesterday and of today. Transfusion Clinique et Biologique 2003; 10: 1-5.
225. Candotti D, Temple J, Sarkodie F, Allain JP. Frequent recovery and broad genotype 2 diversity characterize Hepatitis C virus infection in Ghana, West Africa. J Virol 2003; 77: 7914-23.
226. Lefrere JJ, Allain JP, Prati D, Sauleda S, Reesink H. West Nile virus and blood donors. Lancet 2003; 361: 2083-4.
227. Allain JP, Owusu-Ofori S, Opare-Sem O. Pre-donation screening of blood donors for viral markers: providing safer and cheaper blood. VIIth European congress of International Blood Transfusion Society, 2003 pp141-4.
228. Allain JP. Occult hepatitis B virus infection. Transfusion Clinique et Biologique 2004; 11: 18-25. Rios-Visconti M, Pennington J, Garner SF, Allain JP, Williamson LM. Assessment of removal of human cytomegalovirus from blood components by leucocyte depletion filters using realtime quantitative PCR. Blood 2004; 103: 1137-9.
229. Candotti D, Temple J, Owusu-Ofori S, Allain JP. Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type 1. J Virol Methods 2004; 118: 39-47.
230. Fischetti L, Opare-Sem O, Candotti D, Sarkodie F, Lee H, Allain JP. Molecular epidemiology of HIV in Ghana: dominance of CRF02_AG. J Medical Virology 2004; 73: 158-66.
231. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sanguinis 2004; 86: 83-91.
232. Allain JP. Forum on AIDS, hepatitis and hemophilia. J Throm Haemost 2004; 2: 515-6.
233. Fischetti L, Opare-Sem O, Candotti D, Lee H, Allain JP. Higher viral load may explain the dominance of CRF02_AG in the molecular epidemiology of HIV in Ghana. AIDS 2004; 18, 1208-10.
234. Candotti D, Etiz N, Parsyan A, Allain JP. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol 2004; 78: 12169-78.
235. Allain JP, Anokwa M, Casbard A, Owusu-Ofori S, Dennis-Antwi J. Sociology and behaviour of West African blood donors: the impact of religion on human immunodeficiency virus infection. Vox Sanguinis 2004; 87: 233-40.
236. Roberts D, Allain JP, Kitchen A, Field S, Bates I. Blood transfusion in a global context. M Murphy & DH Pamphilon Eds. Blackwell publisher, 2005; pp 415-23.
237. Owusu-Ofori S, Temple J, Sarkodie F, Anokwa M, Candotti D, Allain JP. Pre-donation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion 2005; 45: 133-40.
238. Allain JP, Candotti D, Sarkodie F, Opare-Sem O. HBsAg does not correlated with HBV DNA. Transfusion 2005; 45: 1039-40..
239. Zahn A, Allain JP. Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. J Gen Virol 2005; 86: 677-685.
240. Dineva MA, Candotti D, Fletcher-Brown F, Allain JP, Lee H. Simultaneous visual detection of multiple viral amplicons by dipstick assay. J Clin Microbiol 2005, 43: 3624-9.
241. Corcoran A, Doyle S, Allain JP, Candotti D, Parsyan A. Evidence of serological cross-reactivity between genotype 1 and genotype 3 erythrovirus infections. J Virol 2005 79: 5238-5239.
242. Lefrère JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, Lefrère F, Girot R, Allain JP, Laperche S. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 2005 106; 2890-95.

243. Li C, Allain JP. Chimeric monoclonal antibodies to the hypervariable region 1 of Hepatitis C virus. J Gen Virol 2005 86; 1709-1716.
244. Owusu-Ofori S, Temple J, Sarkodie F, Candotti D, Allain JP. Pre-donation testing of blood donors in resource-poor settings. Transfusion 2005; 45: 1542-3.
245. Fischetti L, Danso K, Dompreh A, Addo V Haaheim L, Allain JP. Vertical transmission of HIV in Ghanaian women diagnosed in cord blood and post-natal samples. J Med Virol 2005; 77: 351-9.
246. Allain JP. Occult hepatitis B virus infection and transfusion. J Hepatology 2006; 44: 617-8.
247. Li C, Collini P, Danso K, Owusu-Ofori S, Dompreh A, Candotti D, Opare-Sem O, Allain JP. GB virus C and HIV-1 RNA load in single virus and co-infected West African individuals. AIDS 2006; 20: 379-86.
248. Parsyan A, Kerr S, Owusu-Ofori S, Elliott G, Allain JP. Reactivity of genotype-specific recombinant proteins of Human erythrovirus B19 with plasmas from genotype 1 or 3 endemic areas. J Clin Microbiol 2006; 44: 1367-75.
249. Parsyan A, Addo-Yobo E, Owusu-Ofori S, Akpene H, Sarkodie F, Allain JP. Effects of transfusion on human erythrovirus B19 susceptible or infected pediatric recipients in a genotype 3 endemic area. Transfusion 2006; 46: 1593-1600.
250. Li C, Danso K, Addo-Yobo E, Dompreh A, Sarkodie F, Owusu-Ofori S, Allain JP. GB virus C genotype 1 is rarely transmitted vertically but acquired during infancy in West Africa. AIDS 2006; 20: 1458-9.
251. Allain JP, Reesink HW, Lucey C. A European perspective on the management of donors and units testing positive for hepatitis B virus DNA. Transfusion 2006;46:1256-8.
252. Zahn A, Jennings N, Ouwehand WH, Allain JP. Hepatitis C virus interacts with human platelet glycoprotein VI. J Gen Virol 2006; 87: 2243-2251
253. Candotti D, Opare-Sem O, Rezvan H, Sarkodie F, Allain JP. Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood donors with and without elevated alanine amino transferase. J Viral Hepat 2006; 13: 715-24.
254. Candotti D, Danso K, Parsyan A, Dompreh A, Allain JP. Maternal-fetal transmission of human parvovirus B19 genotype 3. J Inf Dis 2006; 194: 608-11.
255. Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain JP, Letowska M. Characterization of HBV DNA positive/HBsAg negative blood donors identified in the Polish NAT screening program. Hepatology 2006; 44:1666-74.
256. Allain JP, Hsu J, Pranmeth M, Hanson D, Stassinopoulos A, Fischetti L, Corash L, Lin L. Quantification of viral inactivation by photochemical treatment with amotosalen and UV A light, using a novel polymerase chain reaction inhibition method with preamplification. J Infect Dis. 2006;194:1737-44.
257. Reesink HW, Allain JP. Management of donors and blood products reactive for hepatitis B virus DNA. Vox Sang. 2006 Nov;91(4):281.
258. Parsyan A. Szmaragd C, Allain JP, Candotti D. Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J Gen Virol 2007; 88: 428-31.
259. Chuang WCM, Sarkodie F, Brown CJ, Owusu-Ofori S, Brown J, Li C, Navarrete C, Klenerman P, Allain JP. Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population. J Med Virol 2007; 79: 724-733.
260. Schmidt M, Themann A, Drexler C, Bayer M, Lanzer G, Menichetti E, Lechner S, Wessin D, Prokoph B, Allain JP, Seifried E, Kai Hourfar M. Blood donor screening for parvovirus B19 in Germany and Austria. Transfusion 2007; 47: 1775-82.
261. Candotti D, Danso K, Allain JP. Maternofetal transmission of Hepatitis B virus genotype E in Ghana, West Africa. J Gen Virol 2007; 88: 2686-95.
262. Odinsen O, Owusu-Ofori S, Dompreh A, Sarkodie F, Opare-Sem O, Parker D, Allain JP. Detection and kinetics of antibody production in the early stages of immunization with Hepatitis B virus vaccine. Clin Vaccine Immunol. 2007; 14: 1623-8.
263. Allain JP. International collaborative study proposal for the characterization of occult hepatitis B virus infection identified by nucleic acid or anti-HBc screening. Vox Sang 2007;92:254-7

264. Zahn A, Li C, Danso K, Candotti D, Owusu-Ofori S, Temple J, Allain JP. Molecular characterization of occult hepatitis B virus in genotype E-infected subjects. J Gen Virol 2008; 89: 409-18.
265. Allain JP, Sarkodie F, Boateng P, Asenso K, Kyerematen E, Owusu-Ofori S. A pool of repeat blood donors can be generated with little expense to the blood center in Sub-Saharan Africa. Transfusion 2008; 48:735-41.
266. Chuang WCM, Allain JP. Differential reactivity of putative genotype 2 hepatitis C virus F protein between chronic and recovered infections. J Gen Virol 2008; 89: 1890–1900.
267. Wendel S, Levi JE, Biagini S, Candotti D, Allain JP. A probable case of hepatitis B virus transfusion transmission revealed after a 13-month-long window period. Transfusion 2008; 48: 1602-8.
268. Candotti D, Grabarczyk P, Ghiazza P, Roig R, Casamitjana N, Iudicone P, Schmidt M, Brird A, Crookes R, Brojer E, Miceli M, Amiri A, Li C, Allain JP. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol 2008; 49; 537-47.
269. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol. 2008; 48: 1022-5.
270. Compston LI, Sarkodie F, Li C, Candotti D, Opare-Sem O, Allain JP. Multiplex real-time PCR for the detection and quantification of latent and persistent viral genomes in cellular or plasma blood fractions. J Virol Methods 2008; 151: 47-54.
271. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-7.
272. Lin YH, Wang Y, Loua A, Day GJ, Qiu Y, Nadala EC Jr, Allain JP, Lee HH. Evaluation of a new HBsAg rapid test with improved sensitivity. J Clin Microbiol 2008; 46: 3319-24.
273. Allain JP, Opare-Sem O, Sarkodie F, Rahman R, Owusu-Ofori S. Deferred donor care in a regional hospital blood center in Ghana. Transfusion 2009; 49: 669-675.
274. Allain JP, Candotti D. Diagnostic algorithm for HBV safe transfusion. Blood Transfusion 2009; 7: 174-182.
275. Meldal BHM, Mojaat Moula N, Barnes IAH, Boukef K, Allain JP. A novel Hepatitis B virus subtype D7 in Tunisian blood donors. J Gen Virol 2009; 90:1622-8.
276. Allain JP, Belkhiri D, Vermeulen M, Crookes R, Cable R, Amiri A, Reddy R, Bird A, Candotti D. Characterization of occult Hepatitis B virus strains in South African blood donors. Hepatology 2009; 90: 1868-76.
277. Wang W, Sarkodie F, Danso K, Addo-Yobo E, Owusu-Ofori S, Allain JP, Li C. Seroprevalence of west Nile virus in Ghana. Viral Immunol 2009;22:17-22.
278. Allain JP. Estimation of HBV transfusion risk. Transfusion 2009; 49: 1019-1021.
279. Busch M, Walderhaug M, Custer B, Allain JP, Reddy R, McDonough B. Risk assessment and cost-effectiveness/utility analysis. Biologicals 2009;37:78-87.
280. Allain JP, Stramer SL, Carneiro-Proietti AB, Martins ML, Lopes da Silva SN, Ribeiro M, Proietti FA, Reesink HW. Transfusion-transmitted infectious diseases. Biologicals 2009;37:71-7.
281. Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009 51:798-809.
282. Garmiri P, Loua A, Haba N, Candotti D, Allain JP. Deletions and recombinations in the core region of Hepatitis B virus (HBV) genotype E strains from asymptomatic blood donors in Guinea, West Africa. J Gen Virol 2009; 90:2442-51.
283. González R, Torres P, Castro E, Barbolla L, Candotti D, Koppelman M, Zaaijer HL, Lelie N, Allain JP, Echevarría JM. Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain. Transfusion 2010 ; 50: 221-30.
284. Compston LI, Li C, Sarkodie F, Owusu-Ofori S, Opare-Sem O, Allain JP. Prevalence of

persistent and latent viruses in untreated patients infected with HIV-1 from Ghana, West Africa. J Med Virol 2009; 81: 1860-8.
285. Grabarczyk P, Garmiri P, Liszewski G, Doucet D, Sulkowska E, Brojer E, Allain JP, Polish Blood Transfusion Centres Viral Study Group. Molecular and serological characterization of hepatitis B virus genotype A and D infected blood donors in Poland. J Viral Hepat 2009 ; 17: 444-52.
286. Magiorkinis G, Magiorkinis E, Paraskevis D, Ho SY, Shapiro B, Pybus OG, Allain JP, Hatzakis A. The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med 2009; 6:e1000198. Epub 2009 Dec 15.
287. Allain JP, Sarkodie F, Asenso-Mensah K, Owusu-Ofori S. Relative safety of first-time volunteer and replacement donors in West Africa. Transfusion 2010; 50: 340-3.
288. Yang MH, Li L, Hung YS, Hung CS, Allain JP, Lin KS, Tsai SJ. The efficacy of individual donation and minipool testing to detect low-level hepatitis B virus DNA in Taiwan. Transfusion 2010;50:65-74.
289. Niederhauser C, Weingand T, Candotti D, Maier A, Tinguely C, Wuillemin WA, Gowland P, Allain JP, Stolz M. Fatal outcome of a hepatitis B virus transfusion-transmitted infection. Vox Sang 2010;98:504-507.
290. Allain JP. Volunteer safer than replacement donor blood: a myth revealed by evidence. Vox Sanguinis; ISBT Science Series 2010; 5: 169-75.
291. Meldal BH, Bon AH, Prati D, Ayob Y, Allain JP. Diversity of Hepatitis B virus infecting Malaysian candidate blood donors is driven by viral and host factors. J Viral Hepat 2010; 18: 91-101.
292. Owusu-Ofori S, Asenso-Mensah K, Boateng P, Sarkodie F, Allain JP. Fostering repeat donations in Ghana. Biologicals 2010;38:47-52.
293. El Ekiaby M, Lelie N, Allain JP. Nucleic acid testing (NAT) in high prevalence-low resource settings. Biologicals 2010;38:59-64.
294. Power JP, El Chaar M, Temple J, Thomas M, Spillane D, Candotti D, Allain JP. HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virus. J Hepatol 2010; 53: 780-7.
295. Wu LT, Curran MD, Ellis J, Parmar S, Ritchie AV, Sharma PI, Allain JP, Jalal H, Zambon M, Lee HH. Nucleic Acid Dipstick Test: Molecular Diagnosis of Pandemic H1N1. J Clin Microbiol. 2010 Jul 28.
296. El Chaar M, Candotti D, Crowthers RA, Allain JP. Impact of Hepatitis B virus surface protein mutations on the diagnosis of occult Hepatitis B virus infection. Hepatology 2010; 52:1600-10.
297. Allain JP. Malaria and transfusion: a neglected subject coming back to the forefront. Clin Infect Dis 2010;51:1199-200.
298. Mahgoub S, Candotti D, Elekiaby M, Allain JP. Hepatitis B virus (HBV) infection and recombination between HBV genotypes D and E in asymptomatic blood donors from Khartoum, Sudan. J Clin Microbiol 2010; 49: 298-306.
299. Allain JP, Farrugia A, Sarkodie F. HIV safety in sub-Saharan Africa. Vox Sang 2011; 100:434-5
300. Yuen MF, Wong DKH, Lee CK, Tanaka Y, Allain JP, Fung J, Leung J, Lin CK, Sugiyama M, Sugauchi F, Mizokami M, Lai CL. Transmissibility of Hepatitis B Infection through Blood Transfusion from Blood Donors with Occult Hepatitis B Virus Infection. Clinical Infectious Diseases, 2011; 52: 624-32.
301. Foglieni B, Candotti D, Guarnori I, Raffaele L, Berzuini A, Spreafico M, Orani A, Rossotti R, Rossi D, Allain JP, Prati D. A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion 2011; 51: 719-30.
302. Candotti D, ElChaar M, Allain JP. Transfusion transmission of hepatitis B virus: still learning more about it. ISBT Science Series 2011; 6: 234-40.
303. Stramer S, Wend U, Candotti D, Forster G, Hollinger B, Dodd R, Allain JP, Gerlich W. Occurrence and characterization of naturally acquired hepatitis B infection among vaccinated blood donors. N Engl J Med 2011: 364:236-47.

304. Allain JP. Moving on from voluntary non-remunerated donors: who is the best donor? Brit J Haematol 2011; 154, 763-69.
305. Garmiri P, Rezvan H, Abolghasemi H, Allain JP. Full genome characterization of hepatitis B virus strains from blood donors in Iran. J Med Virol 2011; 83: 948-52.
306. Zheng X, Ye X, Zhang L, Wang W, Shuai L, Wang A, Zeng J, Candotti D, Allain JP, Li C. Characterization of occult hepatitis B virus infection from blood donors in China. J Clin Microbiol 2011; 49: 1730-7.
307. Allain JP, Cox L. Challenges in hepatitis B detection among blood donors. Current opinion in hematology 2011; 18: 461-6.
308. Cox LE, Arslan O, Allain JP. Characterization of hepatitis B virus in Turkish blood donors, and the prevalence of the SP1 splice variant. J Med Virol 2011; 83: 1321-5.
309. Niederhauser C, Candotti D, Weingand T, Maier A, Tinguely C, Stolz M, Allain JP. Reverse vertical transmission of hepatitis B virus (HBV) infection from a transfusion-infected newborn to her mother. J Hepatol. 2012 Mar;56:734-7.
310. Candotti D, Lin CK, Belkhiri D, Sakuldamrongpanich T, Biswas S, Lin S, Teo D, Ayob Y, Allain JP. Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence. Gut 2012; 61: 1744-53.
311. Freimanis GL, Loua A, Allain JP. HIV-1 subtypes D and F are prevalent in Guinea Conakry. J Clin Virol 2012 ; 53: 350-3.
312. Candotti D, Allain JP. Molecular virology in transfusion medicine laboratory. Blood transfusion 2012; 11: 1-16.
313. Zhang L, Yin S, Tan W, Xiao D, Weng Y, Wang W, Li T, Shi J, Shuai L, Li H, Zhou J, Allain JP, Li C. Recombinant interferon-γ lentivirus co-infection inhibits adenovirus replication ex vivo. PLoS One. 2012;7(8):e42455.
314. Li T, Chen Z, Zeng J, Zhang J, Wang W, Zhang L, Zheng X, Shuai L, Klenerman P, Allain JP, Li C. Impact of host responses on control of hepatitis C virus infection in Chinese blood donors. Biochem Biophys Res Commun. 2011;415:503-8.
315. Allain JP, Candotti D; the ISBT HBV Safety Collaborative Group. Hepatitis B virus in transfusion medicine: Still a problem? Biologicals. 2012; 40: 180-6.
316. O'Brien SF, Yi QL, Fan W, Scalia V, Fearon MA, Allain JP. Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services. Vox Sang 2012; 103: 83-6.
317. El Chaar M, El Jisr T, Allain JP. Hepatitis B DNA splicing in Lebanese blood donors and genotype A-E strains: implications for HBV DNA quantification and infectivity. J Clin Microbiol 2012; 50: 3159-67.
318. Meldal BMH, Sarkodie F, Owusu-Ofori S, Allain JP. Hepatitis E virus infection in Ghanaian blood donors- the importance of immunoassay selection and confirmation. Vox Sanguinis 2012, 104: 30-6.
319. Ala F, Allain JP, Bates I, Boukef K, Boulton F, Brandful J, Dax EM, El Ekiaby M, Farrugia A, Gorlin J, Hassall O, Lee H, Loua A, Maitland K, Mbanya D, Mukhtar Z, Murphy W, Opare-Sem O, Owusu-Ofori S, Reesink H, Roberts D, Torres O, Totoe G, Ullum H, Wendel S. External financial aid to blood transfusion services in sub-Saharan Africa: a need for reflection. PLoS Med 2012;9:e1001309.
320. Freimanis GL, Owusu-Ofori S, Allain JP. Hepatitis B virus infection does not significantly influence Plasmodium parasite density in asymptomatic infection in Ghanaian transfusion recipients. PLos One 2012; 7: e49967.
321. Paraskevis D, Magiorkinis G, Magiorkinis E, Ho SY, Belshaw R, Allain JP, Hatzakis A. Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology 2013; 57: 908-16.
322. Qiu J, Wang W, Wu J, Zhang H, Wang Y, Qiao J, Chen C, Gao GF, Allain JP, Li C. 16. Characterization of periplasmic protein BP26 epitopes of Brucella melitensis reacting with murine monoclonal and sheep antibodies. PLoS One 2012; 7.
323. Freimanis G, Sedegah M, Owusu-Ofori S, Kumar S, Allain JP. Investigating the prevalence of transfusion transmission of Plasmodium within a hyperendemic blood donation system. Transfusion 2013; 53: 1429-41.
324. Zhang L, Yin S, Tan W, Xiao D, Weng Y, Wang W, Li T, Shi J, Shuai L, Li H, Zhou J,

Allain JP, Li C. Recombinant interferon-γ lentivirus co-infection inhibits adenovirus replication ex vivo. PLoS One. 2012;7.
325. Gobbini F, Owusu-Ofori S, Marcelin AG, Candotti D, Allain JP. 17.Human herpesvirus 8 transfusion transmission in Ghana, an endemic region of West Africa. Transfusion 2012; 52: 2294-9.
326. Freimanis GL, Owusu-Ofori S, Allain JP. Hepatitis B virus infection does not significantly influence Plasmodium parasite density in asymptomatic infections in Ghanaian transfusion recipients. PLoS One. 2012;7.
327. Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, Bianco L, Ullum H, Candotti D, Lelie N, Gerlich WH, Chudy M. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion 2013; 53: 1405-1415.
328. Osei EN, Odoi AT, Owusu-Ofori S, Allain JP. Appropriateness of blood product transfusion in the Obstetrics and Gynaecology (O&G) department of a tertiary hospital in West Africa. Transfus Med 2013; 23:160-6.
329. Biswas S, Candotti D, Allain JP. Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection. J Virol 2013; 87: 7882-92.
330. El Chaar M, Atwal S, Freimanis GL, Dinko B, Sutherland CJ, Allain JP. Inactivation of Plasmodium falciparum in whole blood by riboflavin plus irradiation. Transfusion 2013; 53: 3174-83.
331. Asenso-Mensah K, Achina G, Appiah R, Owusu-Ofori S, Allain JP. Can family or replacement blood donors become regular volunteer donors? Transfusion. 2014; 57:797-804.
332. Wu LT, Thomas I, Curran MD, Ellis JS, Parmar S, Goel N, Sharma P, Allain JP, Lee HH. Duplex influenza A/B molecular diagnostic assay intended for point-of-care use. J Clin Microbiol. 2013 Jul 12.
333. Bian Y, Zhao S, Zhu S, Zeng J, Li T, Fu Y, Wang Y, Zheng X, Zhang L, Wang W, Yang B, Zhou Y, Allain JP, Li C. Significance of monoclonal antibodies against the conserved epitopes within non-structural protein 3 helicase of hepatitis C virus. PLoS One 2013 Jul 24; 8.
334. Harrison GL, Pryor J, Malani J, Supuri M, Masta A, Teriboriki B, Toatu T, Penny D, Allain JP, Barnes E, Pybus OG, Klenerman P. Infection frequency of hepatitis C virus and IL28B haplotypes in Papua New Guinea, Fiji, and Kiribati. PLoS One 2013 Aug 20.
335. Li T, Zhu S, Shuai L, Xu Y, Yin S, Bian Y, Wang Y, Zuo B, Wang W, Zhao S, Zhang L, Zhang J, Gao GF, Allain JP, Li C. Infection of common marmosets with hepatitis C virus/GB virus-B chimeras. Hepatology. 2013 Oct 1.
336. Chevaliez S, Challine D, Naija H, Luu TC, Laperche S, Nadala L, Allain JP, Lee HH, Pawlotsky JM. Performance of a new rapid test for the detection of hepatitis B surface antigen in various patient populations. J Clin Virol. 2013 Dec 1.
337. Wang W, Wu J, Qiao J, Weng Y, Zhang H, Liao Q, Qiu J, Chen C, Allain JP, Li C. Evaluation of humoral and cellular immune responses to BP26 and OMP31 epitopes in the attenuated Brucella melitensis vaccinated sheep. Vaccine. 2013 Dec 24.
338. Assennato S, Berzuini Aa, Foglieni B, Spreafico M, Allain JP, Prati D. Parasitemia in blood donors at risk for malaria after several years of residence in Italy. Transfusion 2014; 54:
339. Opare-Sem O, Bedu-Addo G, Karikari P, Boatend P, Sarkodie F, Rahman R, Asenso-Mensah K, Awuah B, Osaei Akoto A, Munin SA, Mensah-Acheampong F, Allain JP, Owusu-Ofori S. Fourteen year experience of a tertiary hospital transfusion committee in West Africa. Transfusion 2014; May 20.
340. Ritchie AV, Ishiro-Lumb I, Edemaga D, Joshi HA, De Ruiter A, Szumilin E, Jendrulek I, McGuire M, Goel N, Sharma P, Allain JP, Lee H. SAMBA HIV semiquantitative test, a new point of care viral load monitoring assay for resource limited settings. J Clin Microbiol 2014; 52: 3377-83.
341. Wang W, Liao Q, Wu X, Hou S, Wang Y, Wu J, Chen C, Shen S, Allain JP, Li C. Potential risk of blood-transfusion-transmitted brucellosis in an endemic area of China. Transfusion 2014; Epub Sept 19.

342. Burnouf T, Emmanuel J, Mbanya D, El-Ekiaby M, Murphy W, Field S, Allain JP. Ebola: a call for blood transfusion strategy in sub-Saharan Africa. Lancet 2014; 384: 1347-8.
343. Li T, Xu Y, Yin S, Liu B, Zhu S, Wang W, Wang Y, Liu F, Allain JP, Li C. Characterization of major histocompatibility complex class 1 allele polymorphism in common marmosets. Tissue Antigens 2014; 84: 568-73.
344. Zheng X, Ye X, Du P, Zeng J, Zhu W, Yang B, Li C, Allain JP. High prevalence of anti-hepatitis B core antigen in hepatitis B virus-vaccinated Chinese blood donors suggests insufficient protection but little threat to blood supply. Transfusion 2014; epub Nov 2.
345. Owusu-Ofori S, Kusi J, Owusu-Ofori A, Freimanis G, Olver C, Martinez CR, Wilkinson S, Mundt JM, Keil SD, Goodrich RP, Allain JP. Treatment of whole blood (WB) with riboflavin and UV light: impact on malaria parasite viability and WB storage. Shock 2014; epub Nov 24.
346. Titmarsh L, Zeh C, Verpoort T, Allain JP, Lee H. Leukodepletion as point of care method for monitoring HIV-1 viral load in whole blood. J Clin Micobiol 2014; epub Nov 26.
347. Enjalbert F, Krysztof D, Candotti D, Allain JP, Stramer S. Comparison of seven hepatitis B virus (HBV) nucleic acid testing assays in selected samples with discrepant HBV marker results from United States blood donors. Transfusion 2014; 54.
348. Li TT, Zhu SM, Shuai LF, Xu YX, Yin S, Bian YX, Wang YZ, Zuo BF, Wang WJ, Zhao SX, Zhang L, Zhang JG, Gao G, Allain JP, Li CY. Infection of common marmosets with Hepatitis C Virus/GB Virus-B chimeras. Hepatology 2014; 59.
349. Spreafico M, Berzuini A, Foglieni B, Candotti D, Raffaele L, Guarnori I, Colli A, Maldini FF, Allain JP, Prati D. Poor efficacy of nucleic acid testing in identifying occult HBV infection and consequences for safety of blood supply in Italy. J Hepatol 2015; 63: 1068-76.
350. Allain JP, Owusu-Ofori A, Assennato S, Marschner S, Goodrich R, Owusu-Ofori S. Prevention of Transfusion-Transmitted Malaria By Treatment of Whole Blood with the Mirasol® PRT System. Blood 2015, 126.
351. Kiyaga C, Lee H, Allain JP. Adherence to Early Infant Diagnosis Testing Algorithm, a Challenge to Early Infant Diagnosis Program in Resource Limited Settings of Uganda. 2015 10.17352/2455-3786.000011.
352. Zhu SM, Li TT, Liu BC, Xu YX, Sun YC, Wang YL, Wang YZ, Shuai LF, Chen ZX, Allain JP, Li CY. Infection of common marmosets with GB virus B chimeric virus encoding for the major nonstructural proteins NS2-4A of hepatitis C virus. J Virol 2016; 90.
353. Allain JP, Assennato S, Osei E, Owusu-Ofori A, Marschner S, Goodrich R, Owusu-Ofori S. Characterization of posttransfusion Plasmodium falciparum infection in semi-immune nonparasitemic patients. Transfusion 2016; 56:
354. Candotti D, Diarra B, Bisseye C, Tao I, Quang K, Sanou M, Laperche S, Sanogo R, Allain JP, Simpore J. Molecular characterization of hepatitis B virus in blood donors from Burkina Faso: Prevalence of quasi-subgenotype A3, genotype E, and mixed infections. J Med Virol 2016; 88.
355. Ye XL, Li T, Xu XX, Du P, Zeng JF, Zhu WG, YangBC, Li CY, Allain JP. Characterisation and follow-up study of occult hepatitis B virus infection in anti-HBc-positive qualified blood donors in southern China. Blood Transfusion 2016; 15: 1-7
356. Allain JP, Owusu-Ofori A, Assennato S, Marschner S, Goodrich R, Owusu-Ofori S. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: The African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 2016; 387: 1753-61.
357. Wang Z, Zeng JF, Li TT, Zheng X, Xu XX, Ye XL, Lu L, Zhu WG, Yang BC, Allain JP, Li CY. Prevalence of hepatitis B surface antigen (HBsAg) in a blood donor population born prior to and after implementation of universal vaccination in Shenzhen, China. BMC infectious Dis 2016; 16: 498-507
358. Allain JP, Goodrich R. Pathogen reduction of whole blood: utility and feasibility. Transfus Med 2017;27 Suppl 5:320-326.
359. Li T, Wang W, Zhang L, Zhou Y, Lai F, Fu Y, Wang C, Yang B, Zhu W, Wu Y, Allain JP, Stevens L, Li C. Designing and Implementing a 5-Year Transfusion Medicine Diploma Program in China. Transfus Med Rev 2017;31:126-131.

360. Allain JP, Sibinga CT. Family donors are critical and legitimate in developing countries. Asian J Transfus Sci 2016;10:5-11.
361. Allain JP, Opare-Sem O. Screening and diagnosis of HBV in low-income and middle-income countries. Nat Rev Gastroenterol Hepatol 2016;13:643-653.
362. Weng YC, Zhang L, Huang JF, Zhao J, Luo PF, Bi SY, Yang ZG, Zhu H, Allain JP, Li CY. A simple and cost-saving phenotypic drug susceptibility testing of HIV-1. Scientific Reports 2016; 6.
363. Li TT, Fu YS, Allain JP, Li CY. Chronic and occult hepatitis B virus infections in the vaccinated Chinese population. Annals of Blood 2016; 2. 4-4.
364. Allain JP. Screen-and-treat for chronic hepatitis B: an overdue issue for sub-Saharan Africa. Lancet Global Health 2016; 4: 507-8.
365. Li JF, Hu FH, Chen SY, Luo PF, He ZP, Wang WJ, Allain JP, Li CY. Characterization of novel Omp31 antigenic epitopes of Brucella melitensis by monoclonal antibodies. BMC Microbiology 2017; 17. 10.1186/s12866-017-1025-3.
366. Li JF, Hu FH, Chen SY, Luo PF, He ZP, Wang WJ, Allain JP, Li CY. Characterization of novel Omp31 antigenic epitopes of Brucella melitensis by monoclonal antibodies. BMC Microbiology 2017; 17:115
367. Zhou S, Li TT, Allain JP, Zhou B, Zhang YM, Zhong M, Fu YS, Li CY. Low occurrence of HBsAg but high frequency of transient occult HBV infection in vaccinated and HBIG-administered infants born to HBsAg positive mothers. J Med Virol 2017; 89.
368. Owusu-Ofori S, Allain JP, Owusu-Ofori A. Prevention of transfusion-transmitted malaria. ISBT Science series 2017; 12: 161-7.
369. Allain JP. Global epidemiology of occult HBV infection. Ann Blood 2017; 1: 1-13.
370. Tang X, Allain JP, Wang H, Rong X, Chen JY, Huang K, Xu R, Wang M, Huang JT, Liao Q, Shan ZG, Luo SX, Li TT, Li CY, Fu YS. Incidence of HBV infection in young Chinese blood donors born after mandatory implementation of neonatal hepatitis B vaccination nationwide. J Viral Hepatitis 2018; 25: 1-9.
371. Zhang WY, Huang JT, Wang M, Song DD, Liao Q, Rong X, Li TT, Allain JP, Ren GL, & Fu YS, Li CY. Characterization of monocytic and granulocytic subsets of myeloid-derived suppressor cells in blood donors with occult hepatitis B virus infection. J Med Virol 2018; 91.
372. Candotti D, Assennato S, Laperche S, Allain JP, Levicnik-Stezinar S. Multiple HBV transfusion transmissions from undetected occult infections: Revising the minimal infectious dose. Gut 2018; 68:1-9.
373. Si J, Li J, Zhang L, Zhang W, Yao J, Li T, Wang W, Zhu W, Allain JP, Fu Y, Li C. A signal amplification system on a lateral flow immunoassay detecting for hepatitis e-antigen in human blood samples. J Med Virol. 2019; 91:1301-1306.
374. Assennato S, Owusu-Ofori S, Osei-Akoto A, Lambert N, Allain JP. Microchimerism in Ghanaian children recipients of whole blood transfusion for severe anaemia. Vox Sanguinis 2018; 114: 1-9.
375. Luo SX, Zhang PL, Ma XR, Qi W, Lu JH, Liu BC, Zhao W, Allain JP, Li CY, Li TT. A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development. Virus Research. 2019; 268: 1-10.
376. Wang, QS, Xu Y, Wang Y, Wang HF, Fu YS, Allain JP, Li CY, Li TT. Seroprevalence of Human Adenovirus Type 5 Neutralizing Antibody in Common Marmosets Determined by a New Set of Two Assays. Viral Immunology 2019; 32. 10.
377. Wang JW, Zhang PL, Zeng JF, Du P, Zheng X, Ye XL, Zhu WG, Fu YS, Candotti D, Allain JP, Li CY, Li TT. Occurrence of occult hepatitis B virus infection associated with envelope protein mutations according to anti-HBs carriage in blood donors. Int J Inf Dis. 2020;92:38-45
378. Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS; Taormina Workshop on Occult HBV Infection Faculty Members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71:397-408.
379. Allain JP. Current approaches to increase blood donations in resource-limited countries. Transfus Med 2019;29:297-310.

380. Seed CR, Allain JP, Lozano M, Laperche S, Gallian P, Gross S, Kwon SY, Oh EY, Kim JN, Chua SS, Lam S, Ang AL, Tsoi WC, Hewitt PE, Davison KL, Tettmar K, O'Flaherty N, Boland F, Williams P, Pomeroy L, Wendel S, Fachini R, Scuracchio P, Carminato P, Fearon M, O'Brien SF, Delage G, Kiely P, Hoad V, Matsubayashi K, Satake M, Taira R, Stramer SL, Sauleda S, Bes M, Piron M, El Ekiaby M, Vermeulen M, Levičnik Stezinar S, Nograšek P, Jarvis LM, Petrik J, Charlewood R, Flanagan P, Grabarczyk P, Kopacz A, Łętowska M, Seifried E, Schmidt M. International Forum on Occult hepatitis B infection and transfusion safety. Vox Sang. 2019;114:e1-e35.
381. Gao L, Rong X, He M, Zhang L, Li TT, Wang WJ, Candotti D, Allain JP, Fu YS, Li CY Metagenomic analysis of potential pathogens from blood donors in Guangzhou, China. Transfusion Medicine 2020;30:61-69.
382. Yang H, Zhang GX, Luo PF, He ZP, Hu FH, Li LH, Allain JP, Li CY, Wang WJ. Detection of Brucellae in peripheral blood mononuclear cells for monitoring therapeutic efficacy of brucellosis infection. Antimicrobial Resistance & Infection Control 2019;8:154..
383. Bisseye C, Mba JM, Ndong J, Kosiorek H, Butterfield R, Mombo L, M'batchi B, Borad M, Nagalo B, Allain JP. Decline in the seroprevalence of syphilis markers among first-time blood donors in Libreville (Gabon) between 2004 and 2016. BMC Public Health 2019; 19: 167-72.
384. Luo SX, Zhao W, Ma XR, Zhang PL, Liu BC, Zhang L, Wang WJ, WangYZ, Fu YS, Allain JP, Li TT, Li CY. A high infectious simian adenovirus type 23 vector based vaccine efficiently protects common marmosets against Zika virus infection. PLOS Neglected Tropical Diseases. 2020; 14. e0008027.
385. Wang J, Zhang P, Zeng J, Du P, Zheng X, Ye X, Zhu W, Fu Y, Candotti D, Allain JP, Li C, Li T. Occurrence of occult hepatitis B virus infection associated with envelope protein mutations according to anti-HBs carriage in blood donors. Int J Infect Dis 2020;92:38-45.
386. Liu B, Ma X, Wang Q, Luo S, Zhang L, Wang W, Fu Y, Allain JP, Li C, Li T. Marmoset Viral Hepatic Inflammation Induced by Hepatitis C Virus Core Protein via IL-32. Front Cell Infect Microbiol. 2020;10:135
387. Yang X, He Z, Zhang G, Lu J, Zhang H, Ren H, Tian Y, Yang H, Chen C, Li L, Fu Y, Allain JP, Li C, Wang W. Evaluation of Reactivity of Monoclonal Antibodies Against Omp25 of Brucella spp. Front Cell Infect Microbiol. 2020;10:145.
388. Mlcochova P, Collier D, Ritchie A, Assennato SM, Hosmillo M, Goel N, Meng B, Chatterjee K, Mendoza V, Temperton N, Kiss L, James LC, Ciazynska KA, Xiong XL, Briggs JAG, Nathan JA, Mescia F, Bergamaschi L, Zhang HG, Barmpounakis P, Demeris N,
389.Skells R, Lyons PA, Bradley J, Baker S, Allain JP, Smith KGC, Bousfield R, Wilson M, Sparkes D, Amoroso G, Gkrania-Klotsas E, Hardwick S, Boyle A, Goodfellow I, Gupta RK. Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. Cell Rep Med. 2020; 1: 100099.
390. Luo S, Zang P, Liu B, Yang C, Liang C, Wang Q, Zhang J, Fu Y, Allain JP, Li T, Zhang Y, Li C. Prime-boost vaccination of mice and Rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates. September 2020 DOI: 10.1101/2020.09.28.311480
391. Zhu S, Liu B, Xu Y, Zhang L, Xia Z, Liu J, Zhou X, Fu Y, Allain JP, Li C, Li T. Two new purification methods of hepatitis C virus particles from serum-free culture system. Hepat Mon 2021; 21: e115727.

Reviews and book chapters 2000-2005

1. Allain JP. Cost and Public Perception. Chapter in Advances in Transfusion Safety. Brown F, Vyas G (eds). Development in Biologicals 2000; 102.
2. Allain JP: Will genome detection replace serology in blood screening for microbial agents? Baillieres Best Pract Res Clin Haematol 2000; 13:615-29.
3. Allain JP: Emerging viral infections relevant to transfusion medicine. Blood Rev 2000; 14:173-181.
4. Allain JP. Emerging Viruses in blood transfusion. Vox Sanguinis 2000; 78: 243-248.
5. Allain-JP. Genomic screening for blood-borne viruses in transfusion settings. Clin Lab Haematol. 2000; 22: 1-10.

6. Allain JP Transfusion risks of yesterday and of today. Transfusion Clinique et Biologique 2003; 10: 1-5.
7. Allain JP, Seghatchian J. Current strategies on pathogen removal/inactivation: an overview. Transfus Apheresis Sci. 2001; 25: 195-7.
8. Seghatchian J, Allain JP. Current strategies for the provision of safer plasma and its derivatives: an update. Transfus Apheresis Sci. 2001; 25: 185-7.
9. Allain JP, Thomas I, Sauleda S. Nucleic acid testing for emerging viral infections. Transfusion Medicine 2002; 12: 275-283.
10. Allain JP. Occult hepatitis B virus infection. Transfusion Clinique et Biologique 2004; 11: 18-25.
11. Allain JP, Owusu-Ofori S, Bates I. Blood transfusion in Sub-Saharan Africa. TATM 2004; 6: 16-23.
12. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sanguinis 2004; 86: 83-91.
13. Roberts D, Allain JP, Kitchen A, Field S, Bates I. Blood transfusion in a global context. M
Murphy & DH Pamphilon Eds. Blackwell publisher, 2005; pp 415-23.
14. Allain JP. Forum on AIDS, hepatitis and hemophilia. J Throm Haemost 2004; 2: 515-6.
15. Allain JP, Lee H. Rapid tests for detection of viral markers in blood transfusion. Expert Rev Mol Diagn 2005; 5: 31-41.
16. Allain JP, Owusu-Ofori S, Bedu-Addo G. Donor management in a teaching hospital blood bank in west Africa. Dev Biol (Basel) 2005; 120: 125-30.
17. Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, Lin L, Stramer S. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfusion Medicine Reviews 2005; 19: 110-26.
18. Allain JP. Hepatitis C virus in blood donation. Lancet 2005; 365: 276-8.
19. Allain JP, Owusu-Ofori S. Approaches to hepatitis safety in sub-Saharan Africa. ISBT Science Series 2006; 1: 89-95.
20. Allain J-P. Epidemiology of Hepatitis B virus and genotype. J Clin Virol 2006; 36: S12-7.
21. Candotti D, Allain JP. The utility of Multiplex NAT in blood screening. Advances in Transfusion Safety. Dax EM, Farrugia A, Vyas GN (eds) 2007: pp71-86.
22. Field SP, Allain JP. Transfusion in Sub-Saharan Africa- does a Western model fit? J Clin Pathol 2007 60:1073-5.
23. Allain JP. International collaborative study proposal for the characterization of occult hepatitis B virus infection identified by nucleic acid or anti-HBc screening. Vox Sang 2007; 92: 254-7.
24. Allain JP, Busch MP. Donation archives and prospective donor-recipient repositories: indispensable tools for monitoring blood safety. Transfusion. 2007; 47: 1110-4.
25. Allain JP, Williamson LM. Reflections about Blood Donation. Transfus Med 2007: 17: 149.
26. Allain JP, Mbanya D. Transfusion en Afrique sous-Saharienne. Le Sang. Tissot JD and Schneider P, Editors, 2011.
27. Allain JP, Candotti D. Hepatitis B virus in Transfusion Medicine: still a problem? Biologicals 2012, 40: 180-6.
28. Allain JP, Cox L. Challenges in hepatitis B detection among blood donors. Curr Opin Hematol 2011; 18: 461-6.
29. Candotti D, Allain JP. Molecular virology in transfusion medicine laboratory. Blood Transfus 2013; 11: 203-16.
31. Lund TC, Hume H, Allain JP, McCullough J, Dzik W. The blood supply in Sub-Saharan Africa: needs, challenges and solutions. Transfusion & Apheresis 2013; epub July
32. Allain JP , Owusu-Ofori A. Infectious Complications of Transfusions in Developing Countries. nova publisher, 2015.